Realcan Pharmaceutical Group Co., Ltd. (002589.SZ) Fundamentals
As of May 24, 2026
TL;DR — Realcan Pharmaceutical Group Co., Ltd. (002589.SZ) fundamentals as of May 24, 2026
Realcan Pharmaceutical Group Co., Ltd. (002589.SZ) trades at a trailing P/E of N/A and a P/B of 0.91x. Return on equity is 37.0%, return on invested capital is 142.0%, and the company carries a debt-to-equity ratio of 1.16. The current ratio sits at 1.11, free cash flow yield is 107.0%, and the dividend yield is 12.0%. MIXED — passes most quality screens but at least one flag warrants a closer look.
For intrinsic value (DCF, owner earnings, Graham number) and the full 5-pillar score, see the 002589.SZ overview page.
Full Fundamentals Table
Every key indicator we track for 002589.SZ fundamentals, grouped by category. Industry median is shown where a sector classification is available.
| Metric | 002589.SZ | Healthcare median | What it measures |
|---|---|---|---|
| Revenue (TTM) | View full statement | - | Trailing twelve-month total revenue |
| Net Income (TTM) | View full statement | - | Bottom-line profit after taxes and interest |
| Free Cash Flow (TTM) | View full statement | - | Cash from operations minus CapEx |
| EPS (TTM) | N/A | - | Earnings per diluted share |
| ROE | 37.0% | 14% | Return on Equity — net income / shareholder equity |
| ROA | 13.0% | - | Return on Assets — net income / total assets |
| ROIC | 142.0% | - | Return on Invested Capital — NOPAT / (debt + equity) |
| P/E (Trailing) | N/A | 22x | Price / earnings — how many years of profit to recoup price |
| P/B | 0.91x | 3.8x | Price / book value — premium over net assets |
| P/S | 0.51x | - | Price / sales — useful when earnings are noisy |
| EV/EBITDA | 19.1x | - | Enterprise value / EBITDA — capital-structure neutral |
| Debt / Equity | 1.16 | 0.55 | Leverage — lower = less reliance on debt |
| Current Ratio | 1.11 | - | Current assets / current liabilities — short-term liquidity |
| Dividend Yield | 12.0% | - | Annual dividend / current price |
5-Year Trend
Indexed revenue growth path for 002589.SZ over the past five fiscal years (base = 100). Used as a quick sanity check on whether the top line is compounding or stalling.
Trend indexed from 1-year revenue growth rate. Full statement available in the analyst tier.
Industry Comparison
Across Healthcare, the median company prints P/E around 22x, P/B near 3.8x, ROE close to 14%, and a debt-to-equity ratio of 0.55. 002589.SZ's reading on each metric is in the ratio table above — anything materially above the median valuation multiple deserves a thesis to justify the premium, anything materially below the median return-on-capital flags an operational gap.
Compare 002589.SZ side-by-side with sector peers in the Healthcare stock list.
Quality Triple Check
Piotroski F-Score
Nine-point checklist for accounting quality and operational efficiency
8/9
PASS
Beneish M-Score
Earnings-manipulation detector — below -2.22 is healthy
-2.40
PASS
Altman Z-Score
Bankruptcy-risk model — above 2.99 is "safe zone"
0.84
FLAG
Verdict: MIXED — passes most quality screens but at least one flag warrants a closer look.
Next steps
- View the full 002589.SZ overview for intrinsic value (DCF), margin of safety, and the 5-pillar VM Score.
- Check the 002589.SZ beta page for volatility vs the S&P 500.
- Look at the 002589.SZ P/E ratio page for the 10-year valuation context.
- Dig into the 002589.SZ debt-to-equity page for leverage trends.
- Run your own model in the DCF calculator.
Frequently asked about 002589.SZ fundamentals
What are the key fundamentals for Realcan Pharmaceutical Group Co., Ltd. (002589.SZ)?↓
The core 002589.SZ fundamentals are P/E N/A, ROE 37.0%, ROIC 142.0%, debt/equity 1.16, and dividend yield 12.0%. The complete ratio table on this page covers revenue, net income, FCF, EPS, ROA, P/B, P/S, EV/EBITDA, and current ratio.
How does 002589.SZ compare to its Healthcare peers?↓
The Healthcare sector median P/E is roughly 22x, ROE 14%, and D/E 0.55. 002589.SZ prints P/E N/A, ROE 37.0%, and D/E 1.16. Use the Industry Comparison row in the ratio table for the full diff.
Does 002589.SZ pass the Quality Triple Check?↓
002589.SZ passes 2 of 3 quality screens (Piotroski F-Score, Beneish M-Score, Altman Z-Score). Detailed verdict above.
How is "fundamentals" different from intrinsic value?↓
Fundamentals describe what the business looks like today: profit, cash flow, leverage, returns on capital. Intrinsic value uses those fundamentals as inputs to a DCF (or similar model) and discounts the future cash flows back to today. Use both — fundamentals tell you whether a business is healthy, intrinsic value tells you whether the price is fair.
How often does ValueMarkers update 002589.SZ fundamentals?↓
Cached financial statements refresh every 12 hours. The ratio table on this page is rebuilt every 6 hours via Next.js ISR, and the underlying FMP data refreshes on each new earnings release.